CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses by Truscott, Steven M et al.




CD46 engagement on human CD4+ T cells
produces T regulatory type 1-like regulation of






Washington University School of Medicine in St. Louis
Claudia Kemper
Washington University School of Medicine in St. Louis
John P. Atkinson
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Truscott, Steven M.; Abate, Getahun; Price, Jeffrey D.; Kemper, Claudia; Atkinson, John P.; and Hoft, Daniel F., ,"CD46 engagement




Steven M. Truscott, Getahun Abate, Jeffrey D. Price, Claudia Kemper, John P. Atkinson, and Daniel F. Hoft
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2492
  Published Ahead of Print 4 October 2010. 
2010, 78(12):5295. DOI: 10.1128/IAI.00513-10. Infect. Immun. 
Claudia Kemper, John P. Atkinson and Daniel F. Hoft
Steven M. Truscott, Getahun Abate, Jeffrey D. Price,
 
Responses 
Regulation of Antimycobacterial T Cell
Produces T Regulatory Type 1-Like 
 T Cells+CD46 Engagement on Human CD4
http://iai.asm.org/content/78/12/5295




This article cites 55 articles, 20 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 




arch 26, 2014 by W










arch 26, 2014 by W







INFECTION AND IMMUNITY, Dec. 2010, p. 5295–5306 Vol. 78, No. 12
0019-9567/10/$12.00 doi:10.1128/IAI.00513-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
CD46 Engagement on Human CD4 T Cells Produces T Regulatory
Type 1-Like Regulation of Antimycobacterial T Cell Responses
Steven M. Truscott,1† Getahun Abate,1,3† Jeffrey D. Price,4§ Claudia Kemper,4¶
John P. Atkinson,4 and Daniel F. Hoft1,2*
Department of Internal Medicine, Division of Immunobiology,1 and Department of Molecular Microbiology and Immunology,2
Saint Louis University, St. Louis, Missouri; St. Mary’s Health Center, St. Louis, Missouri3; and Department of Medicine,
Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri4
Received 17 May 2010/Returned for modification 22 June 2010/Accepted 23 September 2010
Understanding the regulation of human immune responses is critical for vaccine development and treating
infectious diseases. We have previously shown that simultaneous engagement of the T cell receptor (TCR) and
complement regulator CD46 on human CD4 T cells in the presence of interleukin-2 (IL-2) induces potent
secretion of the immunomodulatory cytokine IL-10. These T cells mediate IL-10-dependent suppression of
bystander CD4 T cells activated in vitro with anti-CD3 and anti-CD28 costimulation, reflecting a T regulatory
type 1 (Tr1)-like phenotype. However, CD46-mediated negative regulation of pathogen-specific T cells has not
been described. Therefore, we studied the ability of CD46-activated human CD4 T cells to suppress T cell
responses to Mycobacterium bovis BCG, the live vaccine that provides infants protection against the major
human pathogen Mycobacterium tuberculosis. Our results demonstrate that soluble factors secreted by CD46-
activated human CD4 T cells suppress mycobacterium-specific CD4, CD8, and 92 TCR
 T cells.
Dendritic cell functions were not downregulated in our experiments, indicating that CD46-triggered factors
directly suppress pathogen-specific T cells. Interestingly, IL-10 appeared to play a less pronounced role in our
system, especially in the suppression of 92 TCR
 T cells, suggesting the presence of additional undiscovered
soluble immunoregulatory factors. Blocking endogenous CD46 signaling 3 days after mycobacterial infection
enhanced BCG-specific T cell responses in a subset of volunteers. Taken together, these results indicate that
CD46-dependent negative regulatory mechanisms can impair T cell responses vital for immune defense against
mycobacteria. Therefore, modulating CD46-induced immune regulation could be integral to the development
of improved tuberculosis therapeutics or vaccines.
Regulation of the immune system is critical for the resolu-
tion of immune responses and for the prevention of autoim-
munity. FoxP3 regulatory T cells have taken center stage in
recent years, but other pathways of immune regulation are also
under intense investigation. That the adaptive immune system
regulates the effector arms of innate immunity is a central
paradigm of immunology. No less crucial is the fact that innate
immune mechanisms, such as pattern recognition receptors
and the complement system, also instruct and regulate adap-
tive immunity (18, 25).
CD46, also known as membrane cofactor protein (MCP), is
primarily recognized for its role in complement regulation and
as a receptor for multiple human pathogens (7, 29, 41). Almost
all nucleated cells express this type I transmembrane glyco-
protein. When the cell-attached opsonins C3b and C4b, the
major complement effector molecules, bind to CD46, the
plasma serine protease factor I inactivates these fragments by
limited proteolysis, thereby preventing unwanted complement
activation on host tissue. Pathogens known to utilize CD46 as
a receptor—perhaps to usurp its immunoregulatory properties
(7)—include measles virus, human herpesvirus 6, certain group
A and D adenoviruses, Streptococcus pyogenes, and pathogenic
Neisseria. CD46 may also help to orchestrate certain key bio-
logical processes (27, 39). For example, this molecule is inti-
mately involved in limited and highly regulated complement
activation on self at the inner acrosomal membrane of sper-
matozoa following acrosomal activation (40). Importantly,
CD46 also has signaling capabilities and can transmit intracel-
lular signals in multiple cell types when cross-linked at the cell
surface (25). Either of its two possible cytoplasmic tails can
mediate the activation of distinct signaling pathways upon en-
gagement of the extracellular domain (27, 41; reviewed in
reference 39). Monoclonal antibodies (MAbs), complement
activation fragments (i.e., C3b and C4b dimers), or pathogen
components can act as cross-linking ligands for CD46 to initi-
ate signaling.
In CD4 T cells specifically, CD46 cross-linking initiates
phosphorylation of its cytoplasmic domain by Lck (51), the
activation of Vav and Rac (55), and phosphorylation of the
mitogen-activated protein kinase Erk and the adapter proteins
p120CBL and LAT (2). In the presence of interleukin-2 (IL-2)
and T cell receptor (TCR) stimulation, this CD46 costimula-
tion induces strong proliferation as well as a characteristic
profile of cytokine expression. The latter includes a high level
of IL-10 production, by which these cells suppress the prolif-
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eration of purified bystander T cells (4, 26). However, these
studies analyzed the T cell-immunomodulatory effects of
CD46-activated T cells only on CD3/CD28-activated purified
CD4 T cells or in mixed lymphocyte reactions. The impact of
CD46-induced regulatory mechanisms on antigen-specific T
cells in an autologous system of pathogen infection—a more
physiological setting—has not been analyzed.
To accomplish this, we infected peripheral blood mononu-
clear cells (PBMC) from persons vaccinated with live Myco-
bacterium bovis bacille Calmette-Gue´rin (BCG) or from
healthy individuals with evidence of latent tuberculosis (TB)
infection in the presence of supernatants derived from CD46-
activated CD4 T cells. This experimental system demon-
strated that soluble factors produced by CD46-activated CD4
T cells suppress both proliferation and cytokine production of
mycobacterium-specific CD4, CD8, and  T cells, thus
limiting three major subsets of T cells that protect against M.
tuberculosis.
Our reasoning for selecting this specific experimental in vitro
system to address CD46 biology is the following: first, detailed
functional in vivo characterization of CD46-induced regulatory
pathways is hampered by the lack of a suitable small animal
model. Neither mice nor rats express CD46 on their somatic
cells (39, 47), and an analogous molecule with such immuno-
modulatory function has not yet been described in rodents. In
addition, CD4 T cells from mice transgenic for human CD46
do not demonstrate increased IL-10 production upon concur-
rent TCR and human CD46 stimulation (31; C. Kemper, un-
published observations), which argues that downstream medi-
ators of a corresponding pathway in the mouse are likely not
engaged properly by human CD46. Second, transferring super-
natants from CD46-activated CD4 T cells allows us to ob-
serve regulation of pathogen-specific T cell responses without
engaging CD46 on the responding antimycobacterial T cells
themselves. And third, we have an established model of infec-
tion that has previously been used in a clinical trial to enumer-
ate proliferating and cytokine-producing effector T cell subsets
known to protect against the major human pathogen Mycobac-
terium tuberculosis (11, 20). Importantly, this system allows for
the analysis of autologous, antigen-presenting cell (APC)-me-
diated activation of antigen/pathogen-specific T cells through
major histocompatibility complex (MHC)-TCR interactions.
MATERIALS AND METHODS
Ethics statement. Blood from healthy donors was collected and used according
to the guidelines of the Washington University Medical Center Human Studies
Committee. The protocol for leukapheresis was approved by the Saint Louis
University Institutional Review Board. Written informed consent was obtained
from all donors. PBMC were obtained by Ficoll-Paque (Amersham) centrifuga-
tion of leukapheresis samples from healthy volunteers who were positive for the
purified protein derivative tuberculin skin test (PPD; response of 10-mm
induration 48 to 72 h after a 5-tubercullin units test). PBMC were aliquoted and
stored frozen in liquid nitrogen.
Antibodies, media, and reagents. CD4 T cell cultures were maintained in
RPMI 1640 medium (Gibco Invitrogen) with 10% fetal calf serum and 200 mM
L-glutamine in the presence of 25 U/ml recombinant human IL-2 (BioSource
International, Camarilla, CA). RPMI supplemented with normal 10% pooled
human serum, L-glutamine, and 50 U penicillin–50 mg streptomycin per ml was
used to culture PBMC from PPD volunteers.
The hybridoma line expressing the MAb reactive with human CD3 (clone
OKT3) used for T cell activation was obtained from ATCC (Manassas, VA), and
the MAb was purified by the Rheumatic Diseases Core Center, Washington
University School of Medicine. The CD46-activating MAb utilized in this study,
TRA-2-10, recognizes an epitope within the first complement control repeat
(28). The CD28-activating MAb (CD28.2) and the MAbs used to neutralize
human IL-10 (JES3-9D7) (4), granulocyte-macrophage colony-stimulating factor
(GM-CSF; BVD2-21C11), tumor necrosis factor alpha (TNF-; MAb1), and Fas
ligand (FasL; Nok-2) were purchased from BD Biosciences (San Jose, CA). The
human CD40L/CD154 (MAb 24-31) and transforming growth factor  (TGF-;
MAb 2463) neutralizing antibodies were obtained from eBioscience (San Diego,
CA) and R&D Systems (Minneapolis, MN), respectively. Neutralizing polyclonal
antibodies to the chemokines macrophage inflammatory protein 1 (MIP-1),
MIP-1, and RANTES were obtained from Abcam, Inc. (Cambridge, MA).
Fluorophore-labeled MAbs directed against human CD25 (M-A251), CD4
(SK3), CD8 (SK1), CD3 (SK7),  TCR (11F2), gamma interferon (IFN-; B27),
and granzyme B (GB11) were obtained from BD Biosciences. The mouse non-
specific isotype-matched control MAb MOPC 31c (IgG1) was obtained from
Sigma-Aldrich (St. Louis, MO). All other isotype controls were purchased from
BD Biosciences. Carboxyfluorescein succinimidyl ester (CFSE; Vybrant CFDA
SE cell tracer kit) was obtained from Invitrogen Molecular Probes (Eugene,
OR). Phorbol myristate acetate (PMA; Sigma-Aldrich, St. Louis, MO), ionomy-
cin (Sigma), and a Cytofix/Cytoperm kit (BD Biosciences) were used for restimu-
lation and intracellular staining.
Soluble CD46 (sCD46) was prepared in the Rheumatic Diseases Core Center,
Washington University School of Medicine, by cloning an Escherichia coli codon
usage-optimized cDNA coding for short consensus repeat domains 1 to 4 of
human CD46 into the pET15-b vector. BL21(DE3) bacteria were transfected
with the construct. Recombinant sCD46 was then purified from inclusion bodies
and refolded according to a method described by White et al. (52).
BCG strain and source. The Danish strain of Mycobacterium bovis bacille
Calmette-Gue´rin was obtained from the Statens Serum Institut (Copenhagen,
Denmark).
Purification and stimulation of CD4 lymphocytes. CD4 T lymphocytes
were purified from whole blood by magnetic bead separation using CD4 mi-
crobeads (Miltenyi Biotec, Auburn, CA). In vitro stimulation of isolated CD4 T
cells was performed in flat-bottom 96-well plates coated with 2 g/ml anti-CD3,
anti-CD28, anti-CD46, or a matched IgG1 isotype control MAb. The wells were
washed to remove unbound MAbs, and purified CD4 T lymphocytes (1.5  105
to 2.0  105 cells/well) were added in 100 l of culture medium supplemented
with 25 U/ml recombinant human IL-2. The plates were centrifuged at 250  g
for 2 min and incubated at 37°C in 5% CO2. Supernatants were harvested on day
3. CD3/CD46 activation consistently resulted in approximately 50% IL-10/gran-
zyme B/CD25 positive cells by flow cytometry as previously described (4, 26). In
one set of experiments, soluble CD25, the high-affinity IL-2 receptor  chain
(IL-2R), was removed from both control and regulatory supernatants by im-
munodepletion using anti-CD25 MAb from BD Biosciences coupled to Sepha-
rose 4B beads (Pharmacia Biotech).
Cytokine and chemokine analyses. IL-10, GM-CSF, soluble CD25 (IL-2R),
and/or soluble CD40L present in the supernatants of CD3/CD28 or CD3/
CD46-activated CD4 T cells were measured using the appropriate enzyme-
linked immunosorbent assay (ELISA) kits from BioSource International (Ca-
marillo, CA) or BD Biosciences. Cytokine and chemokine levels produced over
the course of 7-day culturing of PBMC with BCG and supernatant derived from
CD3/CD46-activated human CD4 T cells (3/46 SN) or supernatant derived
from CD3/CD28-activated human CD4 T cells (2/38 SN) were measured using
cytometric bead array kits from BD Biosciences. Data collection was performed
on an LSRII flow cytometer at the Saint Louis University Flow Cytometry Core
Facility, and data analysis was done using FCAP Array software provided by BD
Biosciences.
CFSE-based assay to measure BCG-specific T cell responses in vitro. CFSE-
labeled PBMC (1  106/ml) resuspended in 1 ml complete RPMI medium,
control CD3/CD28 supernatant, or CD3/CD46 supernatant were stimulated with
live BCG (multiplicity of infection [MOI], 1) for 7 days in a 5% CO2, 37°C
humidified incubator. Before staining, the cells were restimulated with PMA (50
ng/ml) and ionomycin (750 ng/ml) in the presence of GolgiStop (0.7 l/ml;
Becton Dickinson) for 2 h. Cells were then washed, stained for T cell surface
markers (CD3, CD4, CD8, and  TCR), fixed, permeabilized, and stained with
MAb specific for IFN-. Flow cytometric acquisition was performed on the
LSRII (BD Biosciences) of the Saint Louis University Flow Cytometry Core
Facility, and analyses were carried out utilizing FlowJo software (TreeStar). A
minimum of 10,000 events were acquired. Absolute numbers of CFSElo/IFN-
T cells for each subset were obtained by multiplying viable cell counts per tube
times the frequency of CFSElo/IFN- T cells for each gated T cell subset
(CD4, CD8, or  TCR) as determined by flow cytometry. For neutraliza-
tion experiments, the appropriate function-neutralizing antibodies were added to
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parallel experimental and control supernatants 30 min prior to combining with
infected PBMC cultures.
DC stimulation of mycobacterium-specific T cells. Dendritic cells (DC) were
generated from adherent monocytes by culture with human IL-4 and GM-CSF as
described previously (46). DC were incubated overnight with BCG (5 CFU per
DC) in the presence or absence of control or regulatory supernatants (0.2 ml).
Infected DC were then irradiated and washed twice with fresh medium. CFSE-
labeled nonadherent PBMC (1 106) and DC (2 104) were cultured for 7 days
and analyzed as described above by flow cytometry to enumerate mycobacteri-
um-specific T cell responses.
Statistical analysis. Nonparametric statistics were applied to the results to
determine statistical significance. The Wilcoxon matched pairs test was applied
to matched pairs of data generated from cells derived from the same individual
(e.g., treated with 3/28 SN or 3/46 SN). Medians are plotted on the bar graphs for
the relevant figures, and single outliers were excluded using the extreme Stu-
dentized deviate test.
RESULTS
Experimental approach. A schematic of our experimental
approach is presented in Fig. 1. BCG stimulates CD4, CD8,
and  T cell recall responses in human PBMC from BCG-
vaccinated or PPD donors (20, 21, 53, 54). Previously, we
quantified these pathogen-specific T cell responses by using
multiparameter flow cytometry to detect proliferating T cells
that secreted effector cytokines (20). Briefly, PBMC from im-
mune donors were labeled with CFSE and infected with BCG.
Proliferation (i.e., CFSE dilution), T cell surface markers, and
effector cytokine secretion (i.e., intracellular cytokine staining
for IFN-) were detected simultaneously for different T cell
subsets. By measuring the frequencies of CFSElo/IFN- cells
and counting total cells, we determined under various condi-
tions absolute numbers of responding CD4, CD8, and TCR
 T cells.
Concurrent engagement of CD3 and CD46 on human CD4
T cells in the presence of IL-2 (	5 U/ml) results in the devel-
opment of an IL-10-producing Tr1-like regulatory phenotype
(4, 16, 17, 26, 38). However, these activation conditions also
induce high granzyme B production as well as contact-depen-
dent cytotoxic activity toward bystander T cells in CD4 T cells
(4, 16, 26). Thus, as a starting point in our study using the
mycobacterial infection model, we first examined the cell con-
tact-independent functions of CD46-activated CD4 T cells
(e.g., cytokines and chemokines) on BCG-specific T cell re-
sponses. T cell supernatants were generated as previously de-
scribed (4, 16, 17, 26, 38) by stimulating purified human CD4
T cells for 3 days with immobilized MAbs to CD3 and CD46 in
the presence of recombinant IL-2. We confirmed the develop-
ment of the regulatory phenotype by monitoring the expression
of IL-10 and granzyme B, as well as suppressive activity. Su-
pernatants were then transferred to PBMC cultures infected
with BCG, and T cell responses were analyzed 7 days postin-
fection (Fig. 1). Supernatants derived from CD3/CD28-acti-
vated CD4 T cells were used as a control in parallel cultures.
Supernatants of CD46-activated CD4 T cells downregulate
mycobacterium-specific T cell responses. When 3/46 superna-
tants were transferred to cultures of PBMC infected with BCG
for 7 days, we detected significantly lower numbers of respond-
ing BCG-specific T cells relative to parallel cultures in which
control 3/28 supernatants were added. Representative dot
plots and summary graphs for multiple PPD donors are
shown in Fig. 2. On average, responding CD4 T cells (CD3/
CD4/CFSElo/IFN-) were reduced 3-fold below control lev-
els, while CD8 (CD3/CD8/CFSElo/IFN-) and  TCR
responders (CD3/TCR /CFSElo/IFN-) were reduced
at least 4-fold below the responses detected in control super-
natants (P 
 0.002 for all subsets), indicating that soluble
factors from the CD46-induced T cells suppressed BCG-spe-
cific CD4, CD8, and  T cell responses.
CD3/CD46-activated CD4 T cells exhibit a higher prolif-
eration rate than CD3/CD28-activated CD4 T cells (2, 26).
To exclude the possibility that the different effects of 3/46 SN
and 3/28 SN were due to unequal depletion of nutrients during
the 3-day initial culture (Fig. 1, left), we concentrated these
supernatants by using a 3-kDa cutoff cellulose membrane and
reconstituted both with fresh medium. We then repeated the
7-day BCG infection of PBMC in the presence of these recon-
stituted supernatants and obtained similar results as before
(Fig. 3). Thus, CD46-mediated suppression of pathogen-spe-
cific T cell responses was mediated by the generation of dis-
crete soluble factors rather than increased depletion of nutri-
ents in regulatory 3/46 SN.
To further confirm that the apparent suppressive effects of
3/46 SN represented dominant inhibitory effects rather than
the absence of growth-enhancing effects, we conducted exper-
iments under additional control activation conditions, includ-
ing PBMC cultures incubated with 3/46 SN or 3/28 control SN
without BCG infection (Fig. 4). Analysis of these cultures after
7 days revealed that both supernatants provided some growth/
stimulatory factors independent of BCG infection which acted
on CD4 and especially CD8 T cells (compare RPMI find-
ings with 3/28 and 3/46 findings in all panels), similar to our
previous findings (26). However, the addition of BCG to 3/28
SN resulted in the expected antigen-specific increases in CD4
and CD8 T cell numbers (compare 3/28 and 3/28 BCG), while
this antigen-specific induction of T cell responses was blocked
when BCG and 3/46 SN were added to parallel cultures of the
same PBMC (compare 3/46 to 3/46 BCG). These results con-
firmed that supernatants from CD46-activated CD4 T cells
have suppressive effects on BCG-specific T cell responses,
compared with effector T cell supernatants (3/28 SN).
Interestingly, we observed that BCG-specific  T cell re-
sponses were consistently suppressed by both 3/28 SN and 3/46
SN compared with BCG-infected cultures incubated in me-
dium alone (Fig. 4C). Still, the suppressive effect of 3/46 SN on
FIG. 1. Generation and transfer of supernatants from CD3/CD46-
activated CD4 T cells. Suppression of mycobacterium-specific CD4,
CD8, and  T cell responses was monitored following transfer of
3-day supernatants from CD46-activated CD4 T cells (or from con-
trol CD28-activated CD4 T cells) to BCG-infected CFSE-labeled
PBMC from PPD donors. After 7 days, intracellular IFN- and
dilution of CFSE were detected in the three T cell subsets by flow
cytometry.
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 T cells was stronger, compared with the control 3/28 SN
condition (Fig. 2B), demonstrating that 3/46 SN provided max-
imal suppression of all three T cell subsets. In addition, super-
natants from CD46-activated CD4 T cells also suppressed 
T cell responses in separate cultures stimulated with purified
phosphoantigen (isopentenyl pyrophosphate) and IL-2 (condi-
tions that specifically activate  T cells without concurrent
CD4 and CD8 T cell stimulation), indicating direct suppres-
sion of  T cells, independent of cross talk with activated
antigen-specific CD4 and CD8 T cells (data not shown).
Mechanisms of CD46-mediated suppression of BCG-stimu-
lated PBMC include other soluble factors in addition to IL-10.
IL-10 secretion is one major pathway of immunosuppression
employed by natural and adaptive regulatory T cells (5, 22, 35).
CD46-activated CD4 T cells also utilize this mechanism to
suppress polyclonally stimulated, purified CD4 T cells (4, 26).
Therefore, we assessed whether IL-10 was responsible for the
regulatory effects of 3/46 SN in our mycobacterium-specific
system. A function-neutralizing anti-IL-10 MAb (4, 16, 26) was
added to PBMC cultures infected with BCG, and T cell re-
sponses were measured at day 7 (Fig. 5). In BCG-infected
cultures with control 3/28 SN, IL-10 neutralization moderately
increased BCG-specific CD4 and CD8 T cell numbers com-
pared to those in BCG-infected cultures with medium alone
(although these differences did not reach statistical signifi-
cance). This is likely due to the combinatorial effects of growth
factors present in the 3/28 SN (Fig. 4) and neutralization of the
low levels of IL-10 generally observed in 3/28 T cell culture SN
(produced by memory CD4 T cells restimulated with plate-
bound anti-CD3 and anti-CD28). Surprisingly, however, neu-
tralization of IL-10 in 3/46 SN consistently resulted at best in
only partial reversal of the suppression of BCG-specific CD4
and CD8 T cells (Fig. 5). These results indicate that an
additional (nonidentified) soluble factor(s) in the 3/46 SN me-
diates suppression of pathogen-specific T cell responses, or
perhaps that CD46-induced cytokine/chemokines have an im-
pact on the cross talk between immunocompetent cells over
the course of the 7-day PBMC culture with BCG. Also, the
suppression of  T cell responses in our system was again
distinct from that of CD4 and CD8 T cells in that neutral-
izing anti-IL-10 appeared to have no effect on the suppression
mediated by 3/28 SN or 3/46 SN.
To identify the additional soluble factors that might be act-
ing in concert with IL-10 to regulate T cell responses in our
system, we analyzed the cytokine/chemokine profiles present in
the PBMC cultures at various time points during the 7-day
BCG culture, with and without 3/46 and 3/28 SN (Table 1).
Throughout the course of the infection, IL-10 and GM-CSF
(produced by CD46-stimulated CD4 T cells [4, 26]) remained
elevated in cultures incubated with 3/46 SN compared with
cultures incubated with 3/28 SN. Additionally, we observed
that TNF- and the chemokines MIP-1, MIP-1, and
RANTES (all of which bind CCR5) were maintained at
higher levels in cultures treated with 3/46 SN, while no
significant differences were detected in IL-1, IL-6, IL-
12p70, IP-10, monocyte chemoattractant protein 1, and vas-
cular endothelial growth factor (VEGF) production (data
not shown). Thus, the ability of 3/46 SN to regulate T cell
responses to BCG appeared to correlate with a unique cy-
tokine/chemokine expression pattern.
FIG. 2. Flow cytometry to detect antimycobacterial CD4, CD8, and  TCR T cells and suppression by 3/46 supernatants. (A) CFSE-
labeled PBMC were cultured in RPMI complete medium (left), in control 3/28 SN cells infected with BCG (middle), or in cells from 3/46 SN and
infected with BCG (right). (B) Responding CD3 CD4, CD3 CD8, or CD3  T cells were enumerated by determining absolute numbers
of CFSElo IFN- T cells after 7 days in culture. Bar graphs indicate the medians of 14 experiments. Asterisks indicate significant differences from
T cell responses in 3/28 SN (P 
 0.002 for all T cell subsets by Wilcoxon matched pairs test).
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We next asked whether TNF- or the CCR5 ligands might
act synergistically with IL-10 to induce the observed potent
downregulation of BCG-specific T cell responses. We blocked
TNF- activity in our system by using a neutralizing MAb and
found no reversal of CD46-mediated suppression (Fig. 6A).
However, the production of TNF- may contribute to or be
required for the initial induction of BCG-specific responses in
vitro, a conclusion also suggested by TNF- production during
BCG infection of PBMC (Table 1, TNF- data). We therefore
could not definitively determine whether the higher level of
TNF- present in 3/46 SN is involved in the suppressive
mechanism. Neutralizing antibodies to MIP-1, MIP-1,
and RANTES did not affect the regulatory capacity of the
3/46 SN, either alone or in combination with neutralizing
anti-IL-10 (data not shown). Similarly, neutralization of
GM-CSF, TGF-, CD40L (CD154), or FasL (CD178) in the
3/46 SN had no effect on the suppressive capacity of 3/46 SN
(Fig. 6A and data not shown). An alternative mechanism of
suppression by regulatory T cells is competition for prosur-
vival cytokines, most notably IL-2 (37). Interestingly,
sCD25, the high-affinity IL-2 receptor, is present at high
levels in the 3/46 SN (Fig. 6B). However, immunodepletion
of sCD25 from 3/46 SN did not impact the ability to suppress
BCG-specific responses (Fig. 6C).
We conclude from our experiments that, although IL-10 is
an expected contributing factor in the CD46-mediated down-
regulation of the pathogen-specific T cell responses in our in
vitro model, additional required suppressive “agents” are yet to
be identified.
Soluble mediators induced by CD46 signaling do not sup-
press DC maturation or antigen presentation. IL-10, depend-
ing on the biological context, has the capacity to suppress T cell
activation and/or APC functions (34). Thus, we assessed
whether 3/46 SN could negatively regulate APC maturation or
presentation of BCG antigens. Immature DC were generated
from peripheral blood monocytes using IL-4 and GM-CSF. DC
were infected with BCG and incubated overnight in medium
alone, in medium with recombinant IL-10, in 3/46 SN, or in
3/46 SN plus anti-IL-10 MAb and subsequently analyzed for
the expression of DC maturation markers (Fig. 7A and B). We
found that culturing the DC in 3/46 SN did not suppress but
rather enhanced maturation, as CD40, CD80, CD83, and HLA
FIG. 3. 3/46 supernatant reconstituted with fresh medium retains immunosuppressive activity. Purified CD4 T cells were activated with
plate-bound MAbs to CD3/CD28 or to CD3/CD46, and supernatants were harvested after 3 days. The supernatants were concentrated 10-fold
using Amicon centrifugal filters with a 3-kDa molecular mass cutoff membrane and then reconstituted to the original volume using fresh serum-free
medium. The reconstituted supernatants were then transferred to CFSE-labeled, BCG-infected PBMC from two donors. Absolute numbers of
CD4 and CD8 responders (CFSElo IFN-) were enumerated by flow cytometry after 7 days.
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class II molecules were detected at higher levels than following
stimulation with BCG alone. The addition of anti-IL-10 did not
significantly alter marker upregulation. As expected, recombi-
nant IL-10 (10 ng/ml) inhibited DC maturation. The amount of
recombinant IL-10 in this control was comparable to that
found in 3/46 SN (Table 1), indicating that the combination of
soluble factors produced upon CD46 stimulation counteracts
the usually inhibitory effects of IL-10 on DC maturation.
Next, to determine whether 3/46 SN affects DC antigen
presentation to autologous, pathogen-specific T cells, we incu-
bated immature DC overnight with BCG in the presence of
3/46 SN, irradiated and washed the DC, and added autologous
nonadherent PBMC from PPD donors. After 7 days, we
enumerated proliferating, IFN--producing CD4, CD8 and
 T cells and found that DC presentation of BCG antigens
was unaffected by preincubation with the 3/46 SN (Fig. 7C).
Neutralization of IL-10 did not add significantly to the number
of responders in any T cell subset analyzed. These data suggest
that the regulation of T cell responses in our system occurs
primarily at the level of the responding T cell and not at the
level of APC function. This is in agreement with our previous
findings demonstrating that DC that have matured in the pres-
ence of 3/46 SN retain the ability to induce potent allogeneic T
cell responses in mixed lymphocyte reactions (4). In that pre-
vious study, soluble CD40L (CD154) and GM-CSF produced
upon CD46 activation of CD4 T cells abrogated the suppres-
FIG. 4. T cell responses to BCG infection exceeded background
levels detected upon supernatant transfer alone and were suppressed
by 3/46 SN. CD3 CD4 CFSElo IFN- T cells (A) and CD3 CD8
CFSElo IFN- T cells (B) were enumerated 7 days after CFSE-
labeled PBMC from five PPD donors were added to medium (RPMI
complete), 3/28 SN, or 3/46 SN with or without BCG infection. Both
supernatants promoted some background stimulation, yet BCG en-
hanced that growth, and this enhancement was specifically suppressed
by 3/46 SN. (C) Both 3/28 SN and 3/46 SN suppressed mycobacterium-
specific  T cells relative to the control condition of PBMC infected
with BCG in RPMI complete medium. In each graph (A to C), the
data are plotted with medians indicated by bars. Asterisks indicate
statistically significant suppression compared to the 3/28 BCG condi-
tion (A and B) or compared to RPMI with BCG infection (C) (n  5;
P 
 0.05 by Wilcoxon matched pairs test).
FIG. 5. CD46-induced suppression of pathogen-specific T cell re-
sponses is not reversed by IL-10 blockade alone. CFSE-labeled PBMC
from six PPD donors were infected with BCG and cultured in control
3/28 SN or 3/46 SN in the presence or absence of a monoclonal
antibody to block IL-10 activity. Responding antimycobacterial CD4,
CD8, and  T cells (A to C, respectively) were enumerated by gating
on the appropriate CD3 CFSElo IFN- subpopulation. For each
graph, the data for six experiments are plotted, with medians indicated
by bars.
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sive effects of IL-10 on DC, thus permitting APC function in
the presence of CD46 signaling.
Endogenous CD46 ligands have differential effects on the
activation and expansion phases of BCG-specific T cell re-
sponses. In preliminary experiments (results not shown), we
found that BCG infection of PBMC in fresh medium, without
CD46 SN addition, could induce a subset of CD4 T cells
phenotypically similar to CD46-activated T cells. Therefore,
we wondered whether natural ligands for CD46 may be pro-
duced during PBMC stimulation with live BCG. The cognate
interaction of human T cells and APCs has been reported to
result in the secretion/generation of activated complement
components, including the CD46 ligands C3b and C4b (45).
Thus, it seemed feasible to expect that during the 7-day course
of BCG infection of human PBMC, CD46 signaling on T cells
may be induced through its locally produced ligands. To assess
this possibility, we added soluble recombinant CD46 (which
interferes with the cross-linking and activation of cell surface-
expressed CD46) to PBMC cultures in fresh medium infected
with mycobacteria (Fig. 8). Addition of the soluble CD46 re-
agent on day 0 of the culture had the unexpected effect of
reducing the number of responding T cells detected on day 7.
This observation implies that CD46 costimulation has an im-
portant positive impact on T cell responses if delivered at the
initiation of T cell activation. In contrast, when soluble CD46
was added to the cultures 3 days postinfection with BCG, the
numbers of responding T cells detectable at day 7 were in-
creased in PBMC from at least a subset of volunteers, indicat-
ing a release from regulatory mechanisms induced by CD46
signaling. However, soluble CD46 added on day 3 of culture
did not enhance T cell responses in PBMC obtained from
some of the volunteers, which suggests that the kinetics of
positive versus negative immunoregulatory effects mediated by
CD46 signaling may vary between individuals. Although we
have not yet been able to demonstrate functional conse-
quences of CD46 cross-linking directly on APC or B cells (4,
14), we cannot exclude the possibility that the presence of
soluble recombinant CD46 in these PBMC cultures affects
TABLE 1. Cytokine levels in BCG-infected PBMC cultures in the presence of 3/28 or 3/46 supernatants from activated CD4 T cells





Level (pg/ml) after infection for:
1 day 3 days 5 days 7 days
GM-CSF Medium 0 BCG 1 90 155 182 184
2 83 94 79 109
3/28 SN 622 BCG-3/28 1 536 503 542 554
2 514 488 498 531
3/46 SN 2,454 BCG-3/46 1 2,109 1,945 2,002 1,967
2 1,990 1,879 1,967 1,945
IL-10 Medium 0 BCG 1 132 69 32 22
2 166 98 43 48
3/28 SN 3,597 BCG-3/28 1 2,313 1,518 1,059 1,048
2 2,390 1,534 1,099 1,195
3/46 SN 11,312 BCG-3/46 1 8,398 5,712 4,352 4,208
2 7,699 5,396 4,114 4,068
TNF- Medium 6 BCG 1 294 225 151 53
2 1,569 354 135 68
3/28 SN 193 BCG-3/28 1 357 350 147 61
2 518 344 141 101
3/46 SN 1,491 BCG-3/46 1 870 349 518 407
2 888 797 452 403
MIP-1 Medium 0 BCG 1 10,129 19,480 16,969 14,123
2 13,669 22,453 15,086 9,248
3/28 SN 3,696 BCG-3/28 1 5,174 8,093 7,107 8,334
2 3,987 6,811 4,810 4,654
3/46 SN 18,330 BCG-3/46 1 18,172 18,489 17,558 17,862
2 14,595 13,669 11,466 13,894
MIP-1 Medium 0 BCG 1 26,561 33,707 30,118 26,818
2 37,772 46,676 42,389 50,143
3/28 SN 16,609 BCG-3/28 1 26,818 31,624 28,142 28,971
2 35,587 40,921 32,727 31,316
3/46 SN 80,633 BCG-3/46 1 69,361 60,449 38,151 45,735
2 75,569 70,105 56,184 56,773
RANTES Medium 279 BCG 1 564 735 1,024 1,881
2 326 384 419 665
3/28 SN 352 BCG-3/28 1 485 721 1,301 1,948
2 303 491 798 984
3/46 SN 1,447 BCG-3/46 1 1,167 911 1,055 1,301
2 735 564 654 956
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other CD46-expressing cells in addition to the pathogen-spe-
cific T cells.
In conclusion, we show here for the first time in an APC-
dependent, antigen-specific, and autologous human system
that CD46-activated CD4 T cells potently downregulate
CD4, CD8, and TCR  T cell proliferation and IFN-
production in response to infection with live mycobacteria.
Soluble factors produced upon CD46 costimulation directly
suppressed responding T cells but not APC function. Although
IL-10 participated in suppression of conventional T cell re-
sponses (CD4 and CD8) to mycobacteria, key soluble me-
diators of CD46-induced regulation remain to be identified.
Surprisingly,  T cell responses were negatively regulated by
both CD46- and “classically” CD28-costimulated T cells, and
this regulation was completely independent of IL-10. Further,
we generated data suggesting that natural ligands (e.g., acti-
vated complement fragments) engage CD46 in our system and
that CD46 engagement appears to promote the initial activa-
tion of antimycobacterial T cell responses but inhibit patho-
gen-specific T cell expansion at later time points.
DISCUSSION
TB, which is caused by the intracellular pathogen Mycobac-
terium tuberculosis, is a global public health concern (8, 43).
Approximately one-third of the world’s population is infected
FIG. 6. Mechanistic investigations of the nature and identity of a 3/46-induced soluble factor(s) that inhibits BCG-specific T cell responses.
(A) Neutralization of TNF-, TGF-, GM-CSF, or CD40L in 3/46 supernatants does not prevent suppression. Supernatant was generated by
activation of purified CD4 T cells with plate-bound MAbs to CD3 and CD46 for 3 days. After a 30-min preincubation with neutralizing MAbs
to TNF-, TGF-, GM-CSF, or CD40L, the 3/46 SN was transferred to CFSE-labeled, BCG-infected PBMC from three donors. Controls included
uninfected PBMC and infected PBMC without supernatant. Medians and ranges are plotted for percentages of CD4, CD8, and  TCR T cells
(CFSElo IFN-) detected by flow cytometry for each condition after 7 days. (B) Higher levels of soluble CD25 were produced in the presence
of IL-2 by CD4 T cells stimulated through CD3/CD46 than with CD3/CD28. Without MAbs (Unstim), minimal soluble CD25 was detected.
Supernatants were collected after 3 days of stimulation, and soluble CD25 was assessed by ELISA. Means of eight experiments (standard errors
of the means) are shown. , P 
 0.05 compared to 3/28 SN-stimulated cells. (C) Depletion of soluble CD25 from 3/46 SN does not reverse
suppression of BCG-specific T cell responses. Purified CD4 T cells were activated with plate-bound MAbs to CD3/CD28 or to CD3/CD46, and
supernatants were harvested after 3 days. Soluble CD25 was removed from both control and regulatory supernatants by immunodepletion using
anti-CD25 MAb coupled to Sepharose beads. Supernatants were then transferred to CFSE-labeled, BCG-infected PBMC from two donors.
Absolute numbers of responding CD4 and CD8 T cells (CFSElo IFN-) were enumerated by flow cytometry after 7 days.




arch 26, 2014 by W







with M. tuberculosis, and significant challenges have hampered
efforts to control its disease manifestations. Although standard
treatment regimens based on five first-line drugs are available,
increasing rates of drug resistance threaten to transform TB
into a virtually untreatable disease (12, 49). The available BCG
vaccines are effective in protecting against disseminated TB
disease manifestations in children but provide only limited
protection against pulmonary disease and the establishment of
latent mycobacterial infection (10). Detailed examination of
the interactions between this pathogen and relevant compo-
nents of the immune system will facilitate the development of
improved TB vaccines and/or treatments.
Immune protection against M. tuberculosis involves multiple
immunocompetent cell types (19). CD4 T cells recognize
mycobacterial epitopes presented by MHC II molecules at the
surface of infected macrophages, the preferred cell type for
mycobacterial replication. IFN- produced by activated CD4
T cells in turn stimulates infected macrophages, increasing
their potential to kill intracellular mycobacteria, a critical ef-
fector mechanism for the control of mycobacterial infection
(23, 24). CD8 T cells also produce IFN-, thereby contribut-
ing to TB protection (13, 15). In addition, CD8 T cells di-
rectly recognize and kill TB-infected macrophages (9, 53). In
vivo, IFN--producing CD8 T cells have been identified
within tissue granulomas from human lung biopsy specimens of
patients with latent M. tuberculosis infection (48). TCR 92

T cells also provide significant support for antimycobacterial
immunity (19, 21, 44, 53). While  T cells normally comprise
only 2 to 5% of total circulating lymphocytes, the number of 
T cells with mycobacterium-specific cytolytic activity increases
FIG. 7. Dendritic cell maturation and antigen-presenting function are unaffected by 3/46 supernatants. DC were preincubated overnight in RPMI
medium alone (no BCG), RPMI with BCG, 3/46 SN with BCG with or without neutralizing anti-IL-10, or RPMI with recombinant human IL-10 (10
ng/ml). DC were then analyzed by flow cytometry to measure cell surface expression of CD40, CD80, CD83, and HLA-DR as indicators of maturation.
3/46 SN did not prevent maturation of DC, as might be expected due to its high IL-10 content; in fact, the 3/46 SN increased expression of maturation
markers. (A) Representative histograms indicate surface staining of DC incubated in medium alone (shaded histogram), with BCG (dotted line), BCG
and 3/46 SN (solid line), or BCG plus 3/46 SN plus anti-IL-10 antibody (dashed line). (B) Mean fluorescence intensity (MFI) values for six individuals,
with medians indicated by bars. (C) DC were infected with BCG overnight in the presence of RPMI or 3/46 SN with or without neutralizing anti-IL-10
antibody and then were washed to remove extracellular BCG. Autologous CFSE-labeled PBMC were then added to detect DC antigen presentation to
mycobacterium-specific T cells. After 7 days, CD4, CD8, and  T cells responding to BCG (CFSElo IFN-) were detected in similar absolute
numbers whether or not DC were pretreated with 3/46 SN. Bars indicate medians for the data generated from six individuals.
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significantly following BCG vaccination (36). Furthermore,
BCG-specific  T cells have the capacity to inhibit the growth
of intracellular mycobacteria (44, 53). We report here that
supernatants from CD4 T cells activated through CD46 co-
stimulation significantly dampen the proliferation and effector
cytokine production of these three major protective T cell
subsets: CD4, CD8, and 92 TCR
 T cells.
Despite the inhibitory effects of 3/46 supernatants on myco-
bacterium-specific CD4, CD8, and 92 TCR
 T cells, we
found that the ability of DC to present mycobacterial antigens
to these T cell subsets was not affected, indicating that 3/46
supernatants have direct inhibitory effects on target T cells.
These results are similar to those we reported previously dem-
onstrating that 3/46 supernatants did not prevent lipopolysac-
charide-induced DC maturation or allogeneic stimulation (4).
The 3/46 supernatants contain high levels of GM-CSF and
sCD40L, which promote DC development and prevent the
inhibitory effects of IL-10 on DC maturation, respectively (4).
Our new data presented here are the first to show that 3/46
supernatants do not interfere with the ability of DC to present
antigens expressed by an infectious pathogen. It is unlikely that
the 7-day duration of the assays was an important mitigating
factor preventing any possible inhibitory effect of the 3/46
supernatants on DC function. Previous reports have demon-
strated that full activation of T cells requires only 4 to 6 h (50),
indicating that the early period of our cocultures was probably
the most critical for the initial DC effects on stimulated myco-
bacterium-specific T cells. Furthermore, the marked suppres-
sive effects of IL-10 alone demonstrate that our assay system
was able to detect inhibitory effects on DC if present. There-
fore, despite the presence of IL-10 in 3/46 supernatants, high
levels of GM-CSF and sCD40L (6) likely prevent the suppres-
sive effects of IL-10 on the ability of DC to present mycobac-
terial antigens to pathogen-specific T cells.
Releasing negative regulation of the immune system may be
a key approach to achieving more complete protection or even
complete clearance of mycobacteria. Although the exact in vivo
induction conditions and functional role(s) of CD46-induced
suppressor T cells are currently not possible to create in a small
animal model (see introduction), evidence for the physiologi-
cal significance of the CD46 regulatory signaling pathway in
humans is emerging. A recent report by Astier et al. estab-
lished a connection between defects in the CD46-mediated
induction of IL-10 in CD4 T cells with multiple sclerosis
(MS), which suggests that CD46 may indeed play a role in the
prevention of autoimmunity in humans (3, 32). Similarly, dys-
functional CD46-mediated IL-10 production in T cells has now
been connected with acute experimental autoimmune enceph-
alomyelitis (EAE) in cynomolgus monkeys (which express
CD46 naturally) (30).
CD46-activated CD4 T cells may function in vivo prefer-
entially at the host-environment interface. Mucosal homing
surface markers and migration patterns have been detected
upon CD46 costimulation (1). Furthermore, CD46 is a recep-
tor for several human pathogens which may be encountered at
mucosal surfaces (7, 29, 41). Utilization of CD46 as a receptor
might allow pathogens to coopt its immunoregulatory proper-
ties to create a local anti-immunogenic milieu that would not
only limit complement activation but also suppress T cell re-
sponses. For example, Bordetella pertussis was observed to in-
duce clonal expansion of antigen-specific regulatory T cells
(Treg) during infection of the respiratory tract (33). These
Treg suppressed the protective local Th1 responses against the
pathogenic bacteria in vivo and in vitro through production of
IL-10. We have found that the binding of the streptococcal M
protein to CD46 induces development of an adaptive Tr1-like
phenotype (38), and our current results open up the possibility
that CD46 signals might also be relevant during mycobacterial
infection in the mucosa of the lung or upper respiratory tract.
In addition to the negative regulation of BCG-specific con-
ventional and unconventional T cells through factors secreted
by CD46-stimulated CD4 T cells, we made another interest-
ing observation: the blockage of “natural” CD46 engagement
through C3b/C4b produced by activated immunocompetent
cells in our system could have substantial effects on BCG-
induced T cell responses. This effect was clearly dependent on
the timing of the CD46 signaling blockade: inhibition of CD46
signals during the effector T cell induction phase blocked Th1
FIG. 8. Endogenous CD46 ligands have differential effects on T cell activation and expansion phases of BCG-induced T cell responses. Soluble
CD46 molecules were produced by refolding of bacterial inclusion body material and then purified to remove endotoxin. This recombinant protein
was found to bind CD46 MAb. As described above, CFSE-labeled human PBMC were infected with BCG in fresh medium. Soluble CD46 (10
g/ml) was added either at day 0 or day 3 of the 7-day culture period to saturate the culture with binding sites for potential ligands to CD46 (and
thus block signaling). CD4, CD8, and  T cells responding to BCG (CFSElo IFN-) were detected by flow cytometry. The data are normalized
to the absolute number of responding T cells in each subset detected in parallel cultures infected with BCG. Asterisks indicate statistically
significant differences between day 0 and day 3 groups (n  8; P 
 0.05 by Wilcoxon matched pairs test).
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activation, while later blockade apparently reduced Treg/Tr1
induction and thereby supported Th1 responses in several do-
nors. These findings are consistent with observations in the
field that have been difficult to reconcile for a number of years.
On one hand, CD3/CD46-activated T cells produce high levels
of IL-10 and can potently suppress the proliferation of by-
stander T cells (4, 26). In contrast, CD46-activated CD4 T
cells also have many characteristics reminiscent of effector Th1
cells, including the following: (i) high proliferative capacity
(26); (ii) high levels of TNF- and IFN- production (4); (iii)
a cytokine secretion profile (including secretion of GM-CSF
and soluble CD40L) that supports the maturation of DC even
in the presence of IL-10 (4); (iv) granzyme B and perforin
synthesis with a concomitant capacity for contact-dependent
cytotoxicity toward autologous activated T cells (17). In fact,
Sanchez et al. (42) demonstrated that CD46 signaling induced
strong Th1 induction in their system with only limited IL-10
secretion. In addition, we recently observed that the amount of
recombinant IL-2 added to CD46-triggered cultures differen-
tially regulates IFN- versus IL-10 production(6). It appears
that the timing of CD46 blockade and the levels of IL-2 present
in vitro can result in disparate and reciprocal effects on regu-
latory and effector T cell functions. Thus, CD46 signals in vivo
might have divergent effects, depending on the timing of T cell
activation and the biological context.
The suppression of T cells by both 3/28 SN and 3/46 SN (Fig.
4 and 5) implies that a distinct mechanism is responsible for the
suppression of these antimycobacterial  T cell responses. Un-
derstanding this mechanism may be crucial for designing vaccines
that stimulate  T cell immunity. We have recently shown that
 T cells provide helper functions for the induction of optimal
adaptive  T cell responses (C. T. Spencer, G. Abate, and D. F.
Hoft, submitted for publication). If the primary importance of
mycobacterium-specific 92 T cells is to rapidly respond and
inhibit early mycobacterial growth and then to facilitate definitive
 T cell protective functions, it is feasible that  T cells may
provide negative feedback to  T cells in order to maintain/
reestablish immune homeostasis. This is one possible explanation
for the suppression of  T cell responses by the supernatants
from 3/28-activated CD4 T cells. Further investigation is re-
quired to explore these relationships.
In summary, we have demonstrated that CD46-activated
CD4 T cells can suppress human mycobacterium-specific
CD4, CD8, and  T cells through soluble mechanisms. The
major suppressive effects were not reversed by neutralizing
IL-10, indicating that additional regulatory mechanisms re-
main to be identified. We made rigorous attempts to elucidate
the molecular mechanisms involved by adding neutralizing an-
tibodies against IL-10, FasL, CD40L, and TGF-, none of
which reversed the suppression. Our data also argue against
mechanisms of nutrient or growth factor depletion. We know
the suppressive factor(s) is greater than 3 kDa, because the
suppressor activities are maintained after concentration across
a 3-kDa molecular mass cutoff membrane followed by recon-
stitution with fresh medium (Fig. 3). It also appears that en-
dogenous ligands for CD46 are involved, based on our soluble
CD46 blocking results. Furthermore, the factor(s) is relatively
stable, retaining functional activity after a freeze-thaw cycle.
On the other hand, in preliminary experiments, we found that
heat inactivation of 3/46 supernatants reversed inhibitory ef-
fects, suggesting that proteins subject to heat-induced denatur-
ation are involved. Future work is needed to further charac-
terize the CD46-triggered inhibitory factors. Nevertheless, it is
clear that CD46 can mediate potent suppression of antimyco-
bacterial immunity in vitro. Now it will be key to determine
whether regulatory signals triggered by CD46 are relevant in
vivo during natural TB infection in humans. If so, it will be
important to identify protocols for modulating this immune
regulation. Specific blockade of immunoregulatory CD46 sig-
nals, as well as adaptive and natural regulatory T cell subsets,
could lead to more effective vaccination or new immunother-
apies for tuberculosis.
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